Inclusion Criteria:  Diagnosis of pancreatic ductal adenocarcinoma Evidence of progression or intolerance to previous standard of care pancreatic cancer systemic or locoregional therapies Patients must have adequate organ function  Exclusion Criteria:  Chemotherapy or other locoregional anti-tumoral therapies performed within 28 days of study treatment initiation Received palliative radiation therapy within 2 weeks or any other radiation therapy within 4 weeks of start of study intervention Has received prior systemic anti-cancer therapy including investigational agents within 4 weeks prior to allocation Has a diagnosis of immunodeficiency (autoimmune disease) or is receiving chronic systemic steroid therapy Clinically significant cardiovascular disease Uncontrolled hypertension Inability to swallow tablets